Abraham Silji's Form 4 filing
West Pharmaceutical Services IncWST · filed Aug 3, 2022
- Accession no.
- 0001562180-22-005843
- Filed
- Aug 3, 2022
- Trade date
- Aug 1, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $1.85M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Abraham SiljiCIK 0001733001 | Officer (Chief Digital & Trans Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2022 | Common Stock | SSaleDisposed | −5,374 | $343.93F1 | −$1,848,279.82 | 3,201.3 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $343.69 to $344.10, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Referenced by the price of 1 transaction in Table I.